drugset / Trial / NCT02943486
Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2
Phase 1/2
Unknown
51 enrolled
Universidad Autónoma de Bucaramanga
Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle · collabInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety and efficacy of using mesenchymal stromal cell derivatives (dac-MSCs) in the treatment of chronic diabetic foot ulcers (type 1 and 2) in adults. A third of the participants will receive dac-MSCs and Triticum vulgare (Fitostimoline) in combination, the other third MSCs and Fitostimoline in combination, and the last third only Fitosimoline. This study will be a randomized, blind, and parallel and controlled-group trial.
Timeline
- Start
- 2017-01
- Primary completion
- 2018-06
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fitostimoline | Unknown | — | Topical |